Cargando…

Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma who had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report

Gefitnib is an oral agent of epidermal growth factor receptor tyrosine kinase inhibitor, and it has a certain efficacy against non-small cell lung cancer. There are some reports that the non-small cell lung cancer patients who experienced disease progression after responding to gefitinib were again...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Su Jin, Lee, Ho Sung, Choi, Jae Sung, Na, Ju Ock, Seo, Ki Hyun, Oh, Mi Hye, Jou, Sung Shick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2012
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376882/ https://www.ncbi.nlm.nih.gov/pubmed/22719810 http://dx.doi.org/10.4021/jocmr816e

Ejemplares similares

Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma
por: Lee, Joo Young, et al.
Publicado: (2012)

Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patients
por: Sugiura, Yasoo, et al.
Publicado: (2013)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
por: Sathyanarayanan, Vishwanath, et al.
Publicado: (2014)

Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma
por: Liu, Chien-Ming, et al.
Publicado: (2015)

The importance of the lepidic component as a prognostic factor in stage I pulmonary adenocarcinoma
por: Moon, Youngkyu, et al.
Publicado: (2016)

Synergistic Effect of HAD-B1 and Afatinib Against Gefitinib Resistance of Non-Small Cell Lung Cancer
por: Song, Si Yeon, et al.
Publicado: (2022)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Alitretinoin Treatment for Gefitinib-Induced Paronychia
por: Lee, Soo Young, et al.
Publicado: (2019)

Progressive Multiple Cystic Changes in Both Lungs in a Patient Treated with Gefitinib for Lung Adenocarcinoma with Multiple Lung Metastases
por: Ryu, Yon Ju, et al.
Publicado: (2014)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma
por: WANG, ZHUN, et al.
Publicado: (2015)

Effect of aerobic exercise on acquired gefitinib resistance in lung adenocarcinoma
por: Yang, Hong, et al.
Publicado: (2021)

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
por: Tang, Mei-Chuan, et al.
Publicado: (2015)

Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC
por: Qin, Yijia, et al.
Publicado: (2016)

A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma
por: Nguyen, Thinh T., et al.
Publicado: (2022)

Rhabdomyolysis Caused by Gefitinib Overdose
por: Obayashi, Shohei, et al.
Publicado: (2021)

Gefitinib: Dermatitis: case report
Publicado: (2022)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
por: Beom, Seung-Hoon, et al.
Publicado: (2016)

Curcumin Induces EGFR Degradation in Lung Adenocarcinoma and Modulates p38 Activation in Intestine: The Versatile Adjuvant for Gefitinib Therapy
por: Lee, Jen-Yi, et al.
Publicado: (2011)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

A lepidic adenocarcinoma mimicking an eosinophilic lung
por: Senhaji, L., et al.
Publicado: (2022)

ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)

The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib
por: Park, Dong Il, et al.
Publicado: (2015)

Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations
por: Jiang, Xuhong, et al.
Publicado: (2020)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

Prognostic impact according to the proportion of the lepidic subtype in stage IA acinar‐predominant lung adenocarcinoma
por: Jeon, Hyun Woo, et al.
Publicado: (2021)

Orbital metastasis secondary to pulmonary adenocarcinoma treated with gefitinib: a case report
por: Koma, Yasuko, et al.
Publicado: (2012)

Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
por: Choi, Hayoung, et al.
Publicado: (2015)

Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report
por: Maeda, Ai, et al.
Publicado: (2016)

Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib
por: Gozzi, Fabrizio, et al.
Publicado: (2021)

CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma
por: He, Jian, et al.
Publicado: (2023)

Unusual presentation of lepidic adenocarcinoma in a healthy female
por: Akhtar, Zaheer, et al.
Publicado: (2022)

Characteristics and Prognostic Nomogram for Primary Lung Lepidic Adenocarcinoma
por: Tang, Hui, et al.
Publicado: (2022)

Predictors of Invasiveness in Adenocarcinoma of Lung with Lepidic Growth Pattern
por: Young, Timothy J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ijkbms7lf8r4d4akvvfplptcvl